Specifically, recent work by Franco et al has unveiled metabolic reprogramming events and actionable metabolic targets, in particular mTOR, in pancreatic cancer cells in response to palbociclib (Franco et al, 2016). The gene discussed is MTOR; the disease is pancreatic neoplasm.